SOH approves the HTAC recommendation on the minor inclusion of an additional dosage strength of potassium citrate [1620 mg (15mEq)] tablet for severe hypocitraturia and recurrent kidney stones in the Philippine National Formulary (PNF) The Secretary of Health (SOH) approved the Health Technology Assessment Council (HTAC) recommendation on the minor inclusion of an additional dosage continue reading : Potassium Citrate [1620 mg (15 mEq)] Tablet
Fourth Dose of COVID-19 Vaccines Among the Immunocompromised Population (ICPs)
The Secretary of Health (SOH) approved the HTAC recommendation on April 21 to finance a fourth dose of COVID-19 Vaccines AstraZeneca, CoronaVac, Moderna, Pfizer-BioNTech, and Sinopharm among the immunocompromised population (ICPs) ages 18 years old and above given at least 3 months after the third dose, and include these vaccines in the Philippine National Deployment and Vaccination Plan for COVID-19 (NDVP). While continue reading : Fourth Dose of COVID-19 Vaccines Among the Immunocompromised Population (ICPs)
Use of Self-Administered Antigen Testing for COVID-19
Date of publication: 07 April 2022 Signed by the Secretary of Health: 28 June 2022 Objectives: HTA Council Recommendation: Evidence Summary:
Vasopressin 20 I.U./mL (I.V./I.M./S.C.)
The Secretary of Health (SOH) approved the HTAC recommendation on the reinclusion of vasopressin in the PNF on 02 March 2022. Link to issuance Vasopressin 20 I.U./mL (I.V./I.M./S.C.) was previously listed in the Philippine National Formulary (PNF); however, it was automatically delisted in 2017 since the drug was no longer registered in the Philippine Food continue reading : Vasopressin 20 I.U./mL (I.V./I.M./S.C.)
Pfizer-BioNTech (10ug/dose) COVID-19 Vaccine for Children 5 to 11 Years Old
Evidence Summary: Document Link